Gunderson Dettmer represented ARCH Venture Partners on the deal. ARCH Venture Partners led the $270 million Series A financing of Orbital Therapeutics, a company focused on enhancing...
Orbital Therapeutics’ $270M Series Financing
Viridos’ $25 Million Series A Financing
Gunderson Dettmer represented Viridos on the deal. Viridos, the leading algae biofuel company, announced its $25 million Series A financing led by Breakthrough Energy Ventures (BEV) and...
Brightseed’s $68 Million Series B Financing
Gunderson Dettmer represented Brightseed on the deal. Brightseed, a San Francisco-based developer of plant nutrient technology, announced its $68 million Series B financing led by Temasek. Brightseed...
Xencor’s $100 Million Collaboration Agreement with Johnson & Johnson
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Xencor on the deal. Xencor, a clinical-stage biopharmaceutical company, announced its $100 million collaboration agreement with Johnson &...
Amgen’s Acquisition of Rodeo Therapeutics
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP advised Amgen Inc on the deal. Amgen Inc (NASDAQ:AMGN) announced its acquisition of Rodeo Therapeutics. Amgen is one of...